Trial · NCT02307682
Outcomes33
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye | Baseline, Week 48 | Full Analysis Set (FAS) - Last Observation Carried Forward (LOCF) | letters | MEAN |
| SECONDARY | Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye | Baseline, Weeks 36, 40, 44, 48 | FAS - LOCF | letters | MEAN |
| SECONDARY | Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48 | Weeks 16, 20, 28, 32, 40, 44, 48 | FAS - efficacy/safety approach | proportion of subjects | NUMBER |
| SECONDARY | Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20) | Weeks 16, 20, 28, 32, 40, 44, 48 | FAS - efficacy/safety approach | proportion of subjects | NUMBER |
| SECONDARY | Proportion of Subjects With Positive q12 Treatment Status up to Week 96 | Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96 | FAS - efficacy/safety approach | proportion of subjects | NUMBER |
| SECONDARY | Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20) | Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96 | FAS - efficacy/safety approach | proportion of subjects | NUMBER |
| SECONDARY | Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | letters | MEAN |
| SECONDARY | Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | letters | MEAN |
| SECONDARY | Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye | Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | letters | MEAN |
| SECONDARY | Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye | Baseline, Weeks 84, 88, 92, 96 | FAS - LOCF | letters | MEAN |
| SECONDARY | Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS-LOCF | percentage of subjects | NUMBER |
| SECONDARY | Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye | Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96 | FAS - LOCF | micrometers | MEAN |
| SECONDARY | Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye | Baseline, Weeks 36, 40, 44, 48 | FAS - LOCF | micrometers | MEAN |
| SECONDARY | Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye | Baseline, Weeks 84, 88, 92, 96 | FAS - LOCF | micrometers | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02307682/outcomes